Investing into China Investing into China Investing into China

Investing into China

Macro 5 minutes to read

Summary:  China seems to be the bright spot to emerge first from the covid19- induced slowdown. The OECD has projected that China will be the only G20 country expected to see growth this year; output for FY2020 is expected to rise 1.8% which is a sharp upward revision from the 3.7% contraction projected back in June.

With stock market valuations reaching all time highs as the world battles a pandemic that has no end in sight, the disconnect to fundamentals has reached an uncomfortable level. The sensible move in any period of uncertainty is always to bet on fundamentals. It makes sense for investors to have exposure to China in their portfolios.

Positive data supports recovery picture

Economic data out of China in recent months supports this picture of recovery. Manufacturing and Service PMIs have come in above 50 and industrial output gained 5.6% in August, all rising for the fourth straight month and returning to pre-covid levels. Chinese retail sales grew by 0.5% in August 2020, the first month of increase since 2019. On all fronts, the economic backdrop is improving.

Chinese Government remains supportive of the economy

China’s decisive and concerted fiscal and monetary stimulus efforts have also acted as an effective backstop to an economic decline. It has propped up its financial sector to ensure credit conditions remain supportive of businesses: the medium-term lending facility (MLF) rate was cut by 20 basis points to 2.95% injecting US$7.9 billion into the banking system. The PBOC has asked banks to sacrifice USD$212 billion in profits in 2020 to finance affordable loans to companies. The State Council authorised a further US$140 billion in local government special purpose bonds to spur infrastructure investments. Other targeted measures include VAT exemptions, loan subsidies, lowered electricity prices, and spending vouchers for its citizens.

The takeaway here is that China remains ready to act to support the economy. With sizable foreign reserves and interest rates well above 0, China still has many levers to pull in its economic toolkit to jumpstart its economy compared to the US and Europe.

First to produce coronavirus Vaccine

A vaccine will provide the ultimate tailwind for China’s recovery story.

Four of the nine vaccine candidates that have progressed to final-stage trials are from companies based in China, mainly CanSino, Sinovac Biotech, and Sinopharm. Top bio-safety scientist, Wu Guizhen, said that the coronavirus vaccine will be ready for public use as early as November or December, making China one of the first to reach this milestone.

Digital push

Unlike most of the world, China seems unlikely to become mired in a long recession, not least because of its rapid digital transformation. Online shopping platforms by Alibaba and, food delivery services by Meituan Dianping, micro-financing platforms by Ant Financial, and payment/ communication apps by Tencent have pushed every-day consumer services online and levelled the playing field between conglomerates and small enterprises. China’s digital economy already accounted for USD$4.7 trillion or 24.8% of GDP in 2018, and the pandemic in 2020 has only accelerated this trend.

The next wave of digital transformation will likely come from the broader adoption of digital technologies by businesses in different sectors that will restructure value chains and boost productivity. Alibaba recently unveiled ‘Xunxi Digital Factory’ which bridges merchants to manufacturers, connecting manufacturing-related data and consumer insights with factory production and management systems to enhance efficiency. This allows merchants to respond to consumer needs, reduce inventory and holding costs, improve profitability and meet personalisation needs. Chinas USD$4.4 trillion manufacturing sector is set to be transformed.

Investing in Chinese tech stocks

Chinese tech stocks should have a place in every investor’s portfolio. This can be expressed via tech focused ETFs like KranShares CSI China Internet ETF (KWEB:arcx), CSOP Hang Seng Tech Index ETF (03033:xhkg), and iShares Hang Seng Tech ETF (03067.xhkg) and also via broader China exposure through iShares MSCI China ETF (MCHI:xnas) or the Schroder ISF Greater China Fund (SISGRCA.MFU), both of  which have tech stocks in their top 10 holdings.

Many Chinese tech firms are also seeking public listings, allowing the average investor to participate in their growth story. The most anticipated IPO of Ant Group, China’s largest digital payments provider and digital finance platform, will be dual listed on both the Hong Kong as well as the Shanghai Star exchange in early October. The IPO is expected to raise a record USD$30B, valuing the company at USD$225B. Investors can trade the Hong Kong listing through their Saxo account on the day of IPO.

Headline Risks

Of course, China’s economic recovery is not without headwinds. Worsening US-China tensions, another wave of coronavirus cases resulting in lockdowns, or a wave of credit defaults will derail the pace of recovery. Investors need to stay vigilant and nimble as always with proper risk management.


  • iShares Hang Seng Tech ETF (03067.xhkg)
  • CSOP Hang Seng Tech Index ETF (03033:xhkg)
  • iShares Hang Seng Tech ETF (03067.xhkg)
  • iShares MSCI China ETF (MCHI:xnas)
  • Schroder ISF Greater China Fund (SISGRCA.MFU)

Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (
- Analysis Disclaimer (
- Notification on Non-Independent Investment Research (

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000

Contact Saxo

Select region


The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.